CR20150417A - Compuestos de azetidiniloxifenilpirrolidina - Google Patents

Compuestos de azetidiniloxifenilpirrolidina

Info

Publication number
CR20150417A
CR20150417A CR20150417A CR20150417A CR20150417A CR 20150417 A CR20150417 A CR 20150417A CR 20150417 A CR20150417 A CR 20150417A CR 20150417 A CR20150417 A CR 20150417A CR 20150417 A CR20150417 A CR 20150417A
Authority
CR
Costa Rica
Prior art keywords
compounds
azetidinyloxyphenylpirrolidine
methyl
hydrogen
formula
Prior art date
Application number
CR20150417A
Other languages
English (en)
Spanish (es)
Inventor
Gary G Deng
Danwen Huang
Joshua O Odingo
Original Assignee
Lilly Co Eli
Memory Pharm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli, Memory Pharm Corp filed Critical Lilly Co Eli
Publication of CR20150417A publication Critical patent/CR20150417A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CR20150417A 2013-03-13 2015-08-14 Compuestos de azetidiniloxifenilpirrolidina CR20150417A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361778546P 2013-03-13 2013-03-13
PCT/US2014/021474 WO2014159012A1 (fr) 2013-03-13 2014-03-07 Composés d'azétidinyloxyphénylpyrrolidine

Publications (1)

Publication Number Publication Date
CR20150417A true CR20150417A (es) 2015-09-16

Family

ID=50382705

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20150417A CR20150417A (es) 2013-03-13 2015-08-14 Compuestos de azetidiniloxifenilpirrolidina

Country Status (39)

Country Link
US (3) US9034864B2 (fr)
EP (2) EP3168216A1 (fr)
JP (2) JP6017708B2 (fr)
KR (2) KR101745304B1 (fr)
CN (2) CN105051034B (fr)
AP (1) AP3850A (fr)
AR (1) AR095015A1 (fr)
AU (1) AU2014241444B2 (fr)
BR (1) BR112015020222B1 (fr)
CA (1) CA2899806C (fr)
CL (1) CL2015002113A1 (fr)
CR (1) CR20150417A (fr)
CY (1) CY1120142T1 (fr)
DK (1) DK2970222T3 (fr)
DO (1) DOP2015000176A (fr)
EA (1) EA026631B1 (fr)
ES (1) ES2616470T3 (fr)
HR (1) HRP20170080T1 (fr)
HU (1) HUE032235T2 (fr)
IL (1) IL240904B (fr)
JO (1) JO3264B1 (fr)
LT (1) LT2970222T (fr)
MA (1) MA38410B1 (fr)
ME (1) ME02592B (fr)
MX (1) MX373636B (fr)
MY (1) MY180006A (fr)
NZ (1) NZ710481A (fr)
PE (1) PE20151669A1 (fr)
PH (1) PH12015502032A1 (fr)
PL (1) PL2970222T3 (fr)
PT (1) PT2970222T (fr)
RS (1) RS55594B1 (fr)
SG (2) SG11201507501YA (fr)
SI (1) SI2970222T1 (fr)
TN (1) TN2015000384A1 (fr)
TW (1) TWI617553B (fr)
UA (1) UA115583C2 (fr)
WO (1) WO2014159012A1 (fr)
ZA (1) ZA201505417B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3264B1 (ar) * 2013-03-13 2018-09-16 Lilly Co Eli مركبات ازيتيدينيل أوكسي فينيل بيروليدين
WO2016033776A1 (fr) * 2014-09-04 2016-03-10 Eli Lilly And Company (2s)-3-[(3s,4s)-3-[(1r)-1-hydroxyéthyl]-4-(4-méthoxy-3-{[1-(5-méthylpyridin-2-yl)azétidin-3-yl]oxy}phényl)-3-méthylpyrrolidin-1-yl]-3-oxopropane-1,2-diol cristallin
TW201625591A (zh) * 2014-09-12 2016-07-16 美國禮來大藥廠 吖丁啶基氧苯基吡咯啶化合物
CA3123995C (fr) * 2018-12-18 2023-05-23 Wuhan Humanwell Innovative Drug Research and Development Center Limited Company Compose phenylpyrrolidine et son utilisation
CN111333625B (zh) * 2018-12-18 2022-10-18 武汉人福创新药物研发中心有限公司 苯基吡咯烷类化合物及其用途
CN111333637B (zh) * 2018-12-18 2022-07-29 武汉人福创新药物研发中心有限公司 苯基吡咯烷类衍生物及其制备方法
WO2021036953A1 (fr) * 2019-08-23 2021-03-04 湖北生物医药产业技术研究院有限公司 Composé phénylpyrrolidine

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5665754A (en) * 1993-09-20 1997-09-09 Glaxo Wellcome Inc. Substituted pyrrolidines
JPH07300455A (ja) * 1994-03-08 1995-11-14 Mitsubishi Chem Corp 3−フェニルピロリジン誘導体
DE19601938A1 (de) * 1996-01-12 1997-07-17 Schering Ag Neue Phosphodiesteraseinhibitoren
US6376489B1 (en) * 1999-12-23 2002-04-23 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
US6258833B1 (en) * 1999-12-23 2001-07-10 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
CZ20031903A3 (cs) * 2001-01-31 2004-07-14 Pfizer Products Inc. Amidové deriváty thiazolyl-, oxazolyl-, pyrrolyl- a imidazolyl karboxylových kyselin užitečné jako inhibitory isozymů PDE4
CA2623657A1 (fr) 2005-09-29 2007-04-12 Bayer Healthcare Ag Inhibiteurs pde et combinaisons de ceux-ci pour traiter des troubles urinaires
TW201206440A (en) * 2010-04-28 2012-02-16 Astellas Pharma Inc Prophylactic or therapeutic agent for diseases associated with pains in urinary organs
EP2569302A1 (fr) * 2010-05-13 2013-03-20 Amgen, Inc Composés d'hétéroaryloxyhétérocyclyle convenant comme inhibiteurs de la pde10
JO3264B1 (ar) * 2013-03-13 2018-09-16 Lilly Co Eli مركبات ازيتيدينيل أوكسي فينيل بيروليدين

Also Published As

Publication number Publication date
EA026631B1 (ru) 2017-04-28
WO2014159012A1 (fr) 2014-10-02
MA38410B1 (fr) 2016-09-30
CN109336865A (zh) 2019-02-15
US9034864B2 (en) 2015-05-19
RS55594B1 (sr) 2017-06-30
TN2015000384A1 (en) 2017-01-03
CN105051034B (zh) 2019-05-21
BR112015020222A8 (pt) 2018-01-23
KR20150119077A (ko) 2015-10-23
US9604967B2 (en) 2017-03-28
AP3850A (en) 2016-09-30
TWI617553B (zh) 2018-03-11
TW201522327A (zh) 2015-06-16
JP2016510759A (ja) 2016-04-11
DOP2015000176A (es) 2015-11-15
PT2970222T (pt) 2017-02-08
MX2015012579A (es) 2016-01-20
MY180006A (en) 2020-11-19
PH12015502032A1 (en) 2016-01-18
ME02592B (fr) 2017-06-20
KR20170013411A (ko) 2017-02-06
IL240904A0 (en) 2015-10-29
EP2970222A1 (fr) 2016-01-20
PL2970222T3 (pl) 2017-06-30
CL2015002113A1 (es) 2016-01-15
CY1120142T1 (el) 2018-12-12
NZ710481A (en) 2020-08-28
KR101745304B1 (ko) 2017-06-08
JP2016216517A (ja) 2016-12-22
ZA201505417B (en) 2022-09-28
SG10201609717YA (en) 2017-01-27
SG11201507501YA (en) 2015-10-29
JP6017708B2 (ja) 2016-11-02
HUE032235T2 (en) 2017-09-28
AP2015008699A0 (en) 2015-09-30
EP2970222B1 (fr) 2016-12-21
CN105051034A (zh) 2015-11-11
LT2970222T (lt) 2017-03-27
ES2616470T3 (es) 2017-06-13
JO3264B1 (ar) 2018-09-16
CA2899806A1 (fr) 2014-10-02
US20140275002A1 (en) 2014-09-18
US9266859B2 (en) 2016-02-23
US20150133423A1 (en) 2015-05-14
MX373636B (es) 2020-04-16
UA115583C2 (uk) 2017-11-27
SI2970222T1 (sl) 2017-02-28
WO2014159012A9 (fr) 2014-12-18
HRP20170080T1 (hr) 2017-03-10
EP3168216A1 (fr) 2017-05-17
US20160122322A1 (en) 2016-05-05
IL240904B (en) 2019-02-28
KR101702797B1 (ko) 2017-02-06
BR112015020222A2 (pt) 2017-07-18
HK1212695A1 (en) 2016-06-17
DK2970222T3 (en) 2017-02-27
AR095015A1 (es) 2015-09-16
MA38410A1 (fr) 2016-02-29
AU2014241444B2 (en) 2016-04-07
EA201591498A1 (ru) 2015-12-30
AU2014241444A1 (en) 2015-08-06
CA2899806C (fr) 2017-07-18
PE20151669A1 (es) 2015-11-12
BR112015020222B1 (pt) 2020-07-14
JP6204557B2 (ja) 2017-09-27

Similar Documents

Publication Publication Date Title
CY1120635T1 (el) Βενζαμιδια αμινοετεροαρυλιου ως αναστολεις κινασης
DOP2017000078A (es) Indazoles sustituidos con bencilo como inhibidores de bub1.
CY1119105T1 (el) Παραγωγα διπυραζολιου ως αναστολεις jak
CR20150470A (es) Derivados de triazolona de piridinilo y piridinilo fusionado
MX2018006148A (es) Inhibidores de cxcr2.
EA201591728A1 (ru) Гетероциклические соединения и способы их применения
MX2018003130A (es) Compuestos de heteroarilo como inhibidores de cinasas asociadas a receptor de interleucina-1 (irak) y usos de los mismos.
MX386935B (es) Profármacos de fumaratos y su uso en el tratamiento de diferentes enfermedades.
MX378288B (es) Inhibidores de pirimidina del fgfr4.
MX2017004200A (es) Compuestos de heteroarilo como inhibidores de tirosina-cinasa de bruton (btk) y usos de estos.
CR20140468A (es) Inhibidores de diacilglicerol aciltransferasa 2
UY34472A (es) Derivados modificados de 4-fenil-piridina
EA201691272A1 (ru) Тетрагидропиридопиразины в качестве модуляторов gpr6
EA201790266A1 (ru) Индолы для применения при инфекции, вызванной вирусом гриппа
CL2015002767A1 (es) Compuestos terapéuticos y composiciones
LT2984166T (lt) Kompozicijos, skirtos mpsi gydymui
EA201690473A1 (ru) Комбинированный состав двух противовирусных соединений
JO3773B1 (ar) معدلات p2x7
EA201690372A1 (ru) Азапиридоновые соединения и их применение
EA201790571A1 (ru) Пирролопиримидины для применения при инфекции, вызванной вирусом гриппа
EA201591634A1 (ru) Дигидропиридопиримидиновые соединения
MX373320B (es) Compuestos inhibidores de pde2.
MX2017014459A (es) Compuestos de tioeter como inhibidores de la nitrificacion.
CL2015002897A1 (es) Inhibidores de bace1
MX384131B (es) Compuestos neurotransmisores de dihidroxifenilo, composiciones y métodos.